BeOne Medicines Ltd. Stockholders Equity

Quick Answer

BeOne Medicines Ltd. reported Stockholders Equity of $4.36 billion for fiscal year 2025.

BeOne Medicines Ltd. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $4.36B +30.9%
2024 $3.33B -5.8%
2023 $3.54B -19.3%
2022 $4.38B -28.5%
2021 $6.13B +58.5%
2020 $3.87B +302.1%
2019 $962.21M -44.7%
2018 $1.74B +159.7%
2017 $669.81M +89.8%
2016 $352.91M +446.8%
2015 -$101.77M -91.9%
2014 -$53.04M -43.5%
2013 -$36.96M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $4.13B +20.2% +9.5%
June 30, 2025 $3.77B +12.0% +7.7%
March 31, 2025 $3.50B +4.1% +5.0%
December 31, 2024 $3.33B -5.8% -3.0%
September 30, 2024 $3.44B -8.7% +2.1%
June 30, 2024 $3.37B -11.4% +0.2%
March 31, 2024 $3.36B -19.2% -5.0%
December 31, 2023 $3.54B -19.3% -6.0%
  • BeOne Medicines Ltd. showed an increase of +30.9% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2013–2025 period, BeOne Medicines Ltd.’s stockholders equity has grown by 11900.1% (from -$36.96 million to $4.36 billion).
  • The most recent figure is from BeOne Medicines Ltd.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment